Autotransplantation for Mantle Cell LymphomaVose, Julie M. MD, MBAThe Cancer Journal: September/October 2012 - Volume 18 - Issue 5 - p 427–431 doi: 10.1097/PPO.0b013e31826dc00b Reviews Buy Abstract Author InformationAuthors Article MetricsMetrics Mantle cell lymphoma (MCL) represents about 5% to 9% of all non-Hodgkin lymphomas according to the World Health Organization. The clinical presentation typically consists of diffuse lymphadenopathy and frequent extranodal involvement of the gastrointestinal tract, blood, and bone marrow, as well as frequent splenomegaly. The median survival with standard immunochemotherapy is approximately 3 to 5 years. High-dose chemotherapy and autologous stem cell transplantation (ASCT) have been used either in first partial or complete remission or at the time of relapse in an attempt to prolong the survival for patients with MCL. Autologous SCT has had disappointing results in patients with relapsed MCL with the expected progression-free survival approximately 20% to 40% in most trials. Therefore, most centers now consider ASCT for eligible MCL patients during first remission. If a complete remission can be obtained with the induction chemotherapy, the clinical results following ASCT in complete remission 1 are improved to 60% to 80% progression-free survival greater than 5 years. However, the median age of patients with MCL is older than 60 years, which does not allow ASCT to be used in all patients with MCL. Research is now focused on reducing the relapse rate after transplantation. From the Division of Hematology/Oncology, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE. The author has disclosed that he/she has no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Julie M. Vose, MD, MBA, Division of Hematology/Oncology, University of Nebraska Medical Center, 98680 Nebraska Medical Center, Omaha, NE 86198. E-mail: email@example.com. © 2012 Lippincott Williams & Wilkins, Inc.